{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:09:47Z","timestamp":1790622587280,"version":"4.1.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00c3\u00b6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["31003A-156270"],"award-info":[{"award-number":["31003A-156270"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.phrs.2019.03.010","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T12:23:26Z","timestamp":1552393406000},"page":"104201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":135,"special_numbering":"C","title":["Mechanisms of statin-associated skeletal muscle-associated symptoms"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4453-9457","authenticated-orcid":false,"given":"Jamal","family":"Bouitbir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda M.","family":"Sanvee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miljenko V.","family":"Panajatovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1696-9815","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.phrs.2019.03.010_bib0005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd1112","article-title":"Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors","volume":"2","author":"Tobert","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.phrs.2019.03.010_bib0010","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM198303173081101","article-title":"Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine","volume":"308","author":"Mabuchi","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.010_bib0015","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1073\/pnas.77.7.3957","article-title":"Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent","volume":"77","author":"Alberts","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.phrs.2019.03.010_bib0020","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.phrs.2019.03.010_bib0025","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40265-016-0613-0","article-title":"Unmet needs in LDL-C lowering: when statins won\u2019t do!","volume":"76","author":"Krahenbuhl","year":"2016","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2005.12.022","article-title":"Protein sensors for membrane sterols","volume":"124","author":"Goldstein","year":"2006","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"issue":"7436","key":"10.1016\/j.phrs.2019.03.010_bib0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/bmj.328.7436.385","article-title":"Variations and increase in use of statins across Europe: data from administrative databases","volume":"328","author":"Walley","year":"2004","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.phrs.2019.03.010_bib0045","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2019.03.010_bib0050","first-page":"1","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012","volume":"177","author":"Gu","year":"2014","journal-title":"NCHS Data Brief"},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jep.12462","article-title":"Statin prescribing according to gender, age and indication: what about the benefit-risk balance?","volume":"22","author":"Wallach-Kildemoes","year":"2016","journal-title":"J. Eval. Clin. Pract."},{"key":"10.1016\/j.phrs.2019.03.010_bib0060","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6024747","article-title":"Beyond statins: emerging evidence for HDL-Increasing therapies and diet in treating cardiovascular disease","volume":"2018","author":"Farrer","year":"2018","journal-title":"Adv. Prev. Med."},{"issue":"9","key":"10.1016\/j.phrs.2019.03.010_bib0065","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s12325-011-0056-7","article-title":"Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial","volume":"28","author":"Eriksson","year":"2011","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0070","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.xphs.2016.01.014","article-title":"Involvement of monocarboxylate transporter 4 expression in statin-induced cytotoxicity","volume":"105","author":"Kikutani","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.010_bib0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/17425251003713519","article-title":"Efflux and uptake transporters as determinants of statin response","volume":"6","author":"Rodrigues","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.010_bib0080","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200528030-00007","article-title":"Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy","volume":"28","author":"Ratz Bravo","year":"2005","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.010_bib0090","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1345\/aph.1D498","article-title":"Rhabdomyolysis in association with simvastatin and amiodarone","volume":"38","author":"Roten","year":"2004","journal-title":"Ann. Pharmacother."},{"issue":"4 Suppl 3","key":"10.1016\/j.phrs.2019.03.010_bib0095","article-title":"Pharmacologic characteristics of statins","volume":"26","author":"McKenney","year":"2003","journal-title":"Clin. Cardiol."},{"issue":"22","key":"10.1016\/j.phrs.2019.03.010_bib0100","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.2174\/1568026614666141203130324","article-title":"Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin","volume":"14","author":"Profumo","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.010_bib0105","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1089\/ars.2014.5836","article-title":"Statins: pleiotropic regulators of cardiovascular redox state","volume":"20","author":"Antoniades","year":"2014","journal-title":"Antioxid. Redox Signal."},{"issue":"20","key":"10.1016\/j.phrs.2019.03.010_bib0110","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/HCO.0000000000000282","article-title":"Statin myopathy: over-rated and under-treated?","volume":"31","author":"Maghsoodi","year":"2016","journal-title":"Curr. Opin. Cardiol."},{"issue":"9326","key":"10.1016\/j.phrs.2019.03.010_bib0120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"H.P.S. Group","year":"2002","journal-title":"Lancet"},{"issue":"9315","key":"10.1016\/j.phrs.2019.03.010_bib0125","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(02)08351-4","article-title":"Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up","volume":"359","author":"Group","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am. Heart J."},{"issue":"22","key":"10.1016\/j.phrs.2019.03.010_bib0135","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9364","key":"10.1016\/j.phrs.2019.03.010_bib0140","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2019.03.010_bib0145","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0150","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjmed.2011.08.007","article-title":"Statin use and musculoskeletal pain among adults with and without arthritis","volume":"125","author":"Buettner","year":"2012","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.010_bib0160","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/ptj\/85.5.459","article-title":"Potential adverse effects of statins on muscle","volume":"85","author":"Tomlinson","year":"2005","journal-title":"Phys. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0165","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mus.21817","article-title":"Statin-associated myopathy and its exacerbation with exercise","volume":"42","author":"Meador","year":"2010","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0175","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.010_bib0180","first-page":"635","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can. J. Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.010_bib0185","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10005","key":"10.1016\/j.phrs.2019.03.010_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)60068-X","article-title":"Immune-mediated necrotising myopathy linked to statin use","volume":"386","author":"Kipfer","year":"2015","journal-title":"Lancet"},{"issue":"17\u201318","key":"10.1016\/j.phrs.2019.03.010_bib0195","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.lfs.2008.02.019","article-title":"Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins","volume":"82","author":"Kobayashi","year":"2008","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.010_bib0200","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bcp.2009.12.007","article-title":"Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy","volume":"79","author":"Mullen","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0205","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/10623329709079868","article-title":"Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin","volume":"5","author":"Morita","year":"1997","journal-title":"Endothelium"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0210","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1006\/bbrc.1994.2112","article-title":"Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors","volume":"202","author":"Nakahara","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2019.03.010_bib0215","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bcp.2018.01.021","article-title":"Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation","volume":"150","author":"Sun","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"21","key":"10.1016\/j.phrs.2019.03.010_bib0220","doi-asserted-by":"crossref","first-page":"9668","DOI":"10.1073\/pnas.88.21.9668","article-title":"Quantitation of prenylcysteines by a selective cleavage reaction","volume":"88","author":"Epstein","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0225","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrm.2015.11","article-title":"Protein prenylation: unique fats make their mark on biology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.phrs.2019.03.010_bib0230","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nchembio834","article-title":"Trafficking and signaling by fatty-acylated and prenylated proteins","volume":"2","author":"Resh","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"14","key":"10.1016\/j.phrs.2019.03.010_bib0235","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1073\/pnas.89.14.6403","article-title":"Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity","volume":"89","author":"Kato","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0240","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.molcel.2012.05.007","article-title":"Cooperative activation of PI3K by Ras and Rho family small GTPases","volume":"47","author":"Yang","year":"2012","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0245","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2005.04.005","article-title":"Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy","volume":"7","author":"Sebti","year":"2005","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0250","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-12-0521","article-title":"Mutant and wild-type Ras: co-conspirators in cancer","volume":"3","author":"Hayes","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2019.03.010_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.029","article-title":"Myotoxicity of statins: mechanism of action","volume":"175","author":"du Souich","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1997.8174","article-title":"HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phrs.2019.03.010_bib0265","article-title":"Ras and Rap1: a tale of two GTPases","author":"Shah","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phrs.2019.03.010_bib0270","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6463807","article-title":"Geranylgeraniol prevents statin-dependent myotoxicity in C2C12 muscle cells through RAP1 GTPase prenylation and cytoprotective autophagy","volume":"2018","author":"Jaskiewicz","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0275","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.taap.2004.04.010","article-title":"Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone","volume":"200","author":"Johnson","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phrs.2019.03.010_bib0280","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tox.2015.01.005","article-title":"Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity","volume":"329","author":"Gee","year":"2015","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0285","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2337\/db06-0823","article-title":"Ceramide- and oxidant-induced insulin resistance involve loss of insulin-dependent Rac-activation and actin remodeling in muscle cells","volume":"56","author":"JeBailey","year":"2007","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0290","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1507\/endocrj.KR-65","article-title":"Insulin receptor signals regulating GLUT4 translocation and actin dynamics","volume":"53","author":"Kanzaki","year":"2006","journal-title":"Endocr. J."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0295","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cellsig.2013.11.007","article-title":"Akt and Rac1 signaling are jointly required for insulin-stimulated glucose uptake in skeletal muscle and downregulated in insulin resistance","volume":"26","author":"Sylow","year":"2014","journal-title":"Cell. Signal."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0300","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/db12-0491","article-title":"Rac1 is a novel regulator of contraction-stimulated glucose uptake in skeletal muscle","volume":"62","author":"Sylow","year":"2013","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.phrs.2019.03.010_bib0305","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.cellsig.2011.05.022","article-title":"Rac1 signalling towards GLUT4\/glucose uptake in skeletal muscle","volume":"23","author":"Chiu","year":"2011","journal-title":"Cell. Signal."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.010_bib0310","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2337\/db12-1148","article-title":"Rac1 signaling is required for insulin-stimulated glucose uptake and is dysregulated in insulin-resistant murine and human skeletal muscle","volume":"62","author":"Sylow","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2019.03.010_bib0315","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.biopha.2016.06.029","article-title":"Simvastatin inhibits glucose uptake activity and GLUT4 translocation through suppression of the IR\/IRS-1\/Akt signaling in C2C12 myotubes","volume":"83","author":"Li","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.010_bib0320","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.20291","article-title":"Molecular clues into the pathogenesis of statin-mediated muscle toxicity","volume":"31","author":"Baker","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.phrs.2019.03.010_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.02.025","article-title":"Mechanisms of insulin resistance by simvastatin in C2C12 myotubes and in mouse skeletal muscle","author":"Sanvee","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.010_bib0330","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.cell.2012.02.035","article-title":"Mitochondria: in sickness and in health","volume":"148","author":"Nunnari","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0335","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2007.12.010","article-title":"New insights into mechanisms of statin-associated myotoxicity","volume":"8","author":"Sirvent","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2019.03.010_bib0340","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/eurheartj\/ehr224","article-title":"Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a\u2019 mitohormesis\u2019 mechanism involving reactive oxygen species and PGC-1","volume":"33","author":"Bouitbir","year":"2012","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.010_bib0345","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1152\/japplphysiol.00107.2011","article-title":"Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress","volume":"111","author":"Bouitbir","year":"1985","journal-title":"J. Appl. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0350","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/ars.2014.6190","article-title":"Statins trigger mitochondrial reactive oxygen species-induced apoptosis in glycolytic skeletal muscle","volume":"24","author":"Bouitbir","year":"2016","journal-title":"Antioxid. Redox Signal."},{"issue":"19-20","key":"10.1016\/j.phrs.2019.03.010_bib0355","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00018-006-6235-z","article-title":"Toxicity of statins on rat skeletal muscle mitochondria","volume":"63","author":"Kaufmann","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0360","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.freeradbiomed.2011.10.449","article-title":"Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes","volume":"52","author":"Kwak","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"12","key":"10.1016\/j.phrs.2019.03.010_bib0365","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.bbamcr.2011.07.019","article-title":"Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt","volume":"1813","author":"Mullen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0370","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.bbrc.2005.02.070","article-title":"Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle","volume":"329","author":"Sirvent","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2019.03.010_bib0375","article-title":"PGC-1beta modulates statin-associated myotoxicity in mice","author":"Singh","year":"2018","journal-title":"Arch. Toxicol."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.010_bib0380","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/eci.12461","article-title":"The role of mitochondria in statin-induced myopathy","volume":"45","author":"Apostolopoulou","year":"2015","journal-title":"Eur. J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0385","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/mus.23309","article-title":"Mitochondria of trained skeletal muscle are protected from deleterious effects of statins","volume":"46","author":"Bouitbir","year":"2012","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.phrs.2019.03.010_bib0390","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0395","first-page":"85","article-title":"Mitochondrial alterations in muscle biopsies of patients on statin therapy","volume":"36","author":"Gambelli","year":"2004","journal-title":"J. Submicrosc. Cytol. Pathol."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0400","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/15376510802305047","article-title":"Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment","volume":"19","author":"Duncan","year":"2009","journal-title":"Toxicol. Mech. Methods"},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0405","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1210\/jc.2017-01561","article-title":"Statins affect skeletal muscle performance: evidence for disturbances in energy metabolism","volume":"103","author":"Allard","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0410","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.taap.2012.06.020","article-title":"Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers","volume":"263","author":"Galtier","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0415","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0420","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjcard.2014.05.047","article-title":"Impact of statin use on exercise-induced cardiac troponin elevations","volume":"114","author":"Eijsvogels","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0425","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0925-4439(95)00028-3","article-title":"Biochemical, physiological and medical aspects of ubiquinone function","volume":"1271","author":"Ernster","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0430","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1152\/japplphysiol.01362.2011","article-title":"Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance","volume":"113","author":"Muraki","year":"1985","journal-title":"J. Appl. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0435","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.taap.2003.08.013","article-title":"Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats","volume":"194","author":"Schaefer","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phrs.2019.03.010_bib0440","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","article-title":"Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials","volume":"99","author":"Banach","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0445","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study","volume":"33","author":"Ghirlanda","year":"1993","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0450","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0009-9236(95)90266-X","article-title":"Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans","volume":"57","author":"Laaksonen","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0455","first-page":"517","article-title":"Serum and muscle tissue ubiquinone levels in healthy subjects","volume":"125","author":"Laaksonen","year":"1995","journal-title":"J. Lab. Clin. Med."},{"issue":"23","key":"10.1016\/j.phrs.2019.03.010_bib0460","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0465","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0470","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14017431.2012.756119","article-title":"No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy","volume":"47","author":"Bogsrud","year":"2013","journal-title":"Scand. Cardiovasc. J."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0475","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","article-title":"Effect of coenzyme Q10 supplementation on statin-induced myalgias","volume":"110","author":"Bookstaver","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0480","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.phrs.2019.03.010_bib0485","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am. J. Cardiol."},{"issue":"10","key":"10.1016\/j.phrs.2019.03.010_bib0490","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2019.03.010_bib0495","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.12659\/MSM.890777","article-title":"Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study","volume":"20","author":"Skarlovnik","year":"2014","journal-title":"Med. Sci. Monit."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0500","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.010_bib0505","doi-asserted-by":"crossref","first-page":"16067","DOI":"10.3390\/ijms160716067","article-title":"Mevalonate pathway blockade, mitochondrial dysfunction and autophagy: a possible link","volume":"16","author":"Tricarico","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"6899","key":"10.1016\/j.phrs.2019.03.010_bib0510","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nature00904","article-title":"Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres","volume":"418","author":"Lin","year":"2002","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0515","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1210\/er.2002-0012","article-title":"Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator","volume":"24","author":"Puigserver","year":"2003","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0520","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s13105-017-0576-y","article-title":"Multi-regulatory network of ROS: the interconnection of ROS, PGC-1 alpha, and AMPK-SIRT1 during exercise","volume":"73","author":"Thirupathi","year":"2017","journal-title":"J. Physiol. Biochem."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.010_bib0525","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.clpt.6100124","article-title":"Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin","volume":"81","author":"Schick","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.010_bib0530","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/mus.22236","article-title":"Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise","volume":"44","author":"Meador","year":"2011","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0535","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/ars.2018.7518","article-title":"Autophagy: a lysosome-dependent process with implications in cellular redox homeostasis and human disease","volume":"30","author":"Ryter","year":"2019","journal-title":"Antioxid. Redox Signal."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0540","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12698","article-title":"PGC-1alpha promotes exercise-induced autophagy in mouse skeletal muscle","volume":"4","author":"Halling","year":"2016","journal-title":"Physiol. Rep."},{"issue":"9","key":"10.1016\/j.phrs.2019.03.010_bib0545","doi-asserted-by":"crossref","first-page":"C710","DOI":"10.1152\/ajpcell.00380.2014","article-title":"Role of PGC-1alpha during acute exercise-induced autophagy and mitophagy in skeletal muscle","volume":"308","author":"Vainshtein","year":"2015","journal-title":"Am. J. Physiol., Cell Physiol."},{"issue":"14","key":"10.1016\/j.phrs.2019.03.010_bib0550","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1089\/ars.2013.5416","article-title":"Mitophagy is required for acute cardioprotection by simvastatin","volume":"21","author":"Andres","year":"2014","journal-title":"Antioxid. Redox Signal."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0555","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cell.2005.02.001","article-title":"Mitochondria, oxidants, and aging","volume":"120","author":"Balaban","year":"2005","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0560","doi-asserted-by":"crossref","first-page":"C844","DOI":"10.1152\/ajpcell.00402.2005","article-title":"Type II skeletal myofibers possess unique properties that potentiate mitochondrial H(2)O(2) generation","volume":"290","author":"Anderson","year":"2006","journal-title":"Am. J. Physiol., Cell Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0565","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cell.2015.10.001","article-title":"Mitochondrial ROS signaling in organismal homeostasis","volume":"163","author":"Shadel","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0570","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-induced myopathy is associated with mitochondrial complex III inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0575","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/01926230590908213","article-title":"Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity","volume":"33","author":"Westwood","year":"2005","journal-title":"Toxicol. Pathol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0580","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/toxsci\/kfi305","article-title":"Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity","volume":"88","author":"Seachrist","year":"2005","journal-title":"Toxicol. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.010_bib0585","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000213279","article-title":"Effect of exercise training on antioxidant and metabolic functions in senescent rat skeletal muscle","volume":"37","author":"Ji","year":"1991","journal-title":"Gerontology"},{"issue":"6","key":"10.1016\/j.phrs.2019.03.010_bib0590","doi-asserted-by":"crossref","first-page":"C1208","DOI":"10.1152\/ajpcell.00226.2006","article-title":"Statin-induced apoptosis and skeletal myopathy","volume":"291","author":"Dirks","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0595","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/jpet.105.086462","article-title":"Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells","volume":"314","author":"Sacher","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.phrs.2019.03.010_bib0600","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbamcr.2015.04.010","article-title":"The AKT\/mTOR signaling pathway plays a key role in statin-induced myotoxicity","volume":"1853","author":"Bonifacio","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0605","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1152\/physrev.00026.2013","article-title":"Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release","volume":"94","author":"Zorov","year":"2014","journal-title":"Physiol. Rev."},{"issue":"17","key":"10.1016\/j.phrs.2019.03.010_bib0610","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1242\/dev.137075","article-title":"Proliferation, survival and metabolism: the role of PI3K\/AKT\/mTOR signalling in pluripotency and cell fate determination","volume":"143","author":"Yu","year":"2016","journal-title":"Development"},{"issue":"5","key":"10.1016\/j.phrs.2019.03.010_bib0615","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s00204-016-1871-z","article-title":"IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes","volume":"91","author":"Bonifacio","year":"2017","journal-title":"Arch. Toxicol."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0620","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/ncb0203-87","article-title":"Signalling pathways that mediate skeletal muscle hypertrophy and atrophy","volume":"5","author":"Glass","year":"2003","journal-title":"Nat. Cell Biol."},{"issue":"10","key":"10.1016\/j.phrs.2019.03.010_bib0625","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.biocel.2005.04.018","article-title":"Skeletal muscle hypertrophy and atrophy signaling pathways","volume":"37","author":"Glass","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.010_bib0630","doi-asserted-by":"crossref","first-page":"C995","DOI":"10.1152\/ajpcell.00520.2010","article-title":"Glycogen synthase kinase-3beta is required for the induction of skeletal muscle atrophy","volume":"301","author":"Verhees","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"12","key":"10.1016\/j.phrs.2019.03.010_bib0635","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0640","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1113\/jphysiol.2008.164699","article-title":"Blunted Akt\/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy","volume":"587","author":"Mallinson","year":"2009","journal-title":"J. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0645","doi-asserted-by":"crossref","first-page":"E564","DOI":"10.1152\/ajpendo.00383.2010","article-title":"Simvastatin represses protein synthesis in the muscle-derived C(2)C(1)(2) cell line with a concomitant reduction in eukaryotic initiation factor 2B expression","volume":"300","author":"Tuckow","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"9716","key":"10.1016\/j.phrs.2019.03.010_bib0650","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.phrs.2019.03.010_bib0655","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00125-015-3528-5","article-title":"Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort","volume":"58","author":"Cederberg","year":"2015","journal-title":"Diabetologia"},{"issue":"9841","key":"10.1016\/j.phrs.2019.03.010_bib0660","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.03.010_bib0665","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"Bmj"},{"issue":"10","key":"10.1016\/j.phrs.2019.03.010_bib0670","doi-asserted-by":"crossref","first-page":"18677","DOI":"10.3390\/ijms151018677","article-title":"Molecular mechanisms for the regulation of insulin-stimulated glucose uptake by small guanosine triphosphatases in skeletal muscle and adipocytes","volume":"15","author":"Satoh","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2019.03.010_bib0675","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-5793(01)02242-6","article-title":"Protein kinase B (PKB\/Akt)--a key regulator of glucose transport?","volume":"492","author":"Hajduch","year":"2001","journal-title":"FEBS Lett."},{"issue":"Pt 1","key":"10.1016\/j.phrs.2019.03.010_bib0680","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/BJ20050887","article-title":"AS160, the Akt substrate regulating GLUT4 translocation, has a functional Rab GTPase-activating protein domain","volume":"391","author":"Miinea","year":"2005","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.010_bib0685","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085721","article-title":"Simvastatin inhibits glucose metabolism and legumain activity in human myotubes","volume":"9","author":"Smith","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2019.03.010_bib0690","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bbrc.2016.10.026","article-title":"Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3beta phosphorylation","volume":"480","author":"Yaluri","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.010_bib0695","doi-asserted-by":"crossref","first-page":"E591","DOI":"10.1152\/ajpendo.00073.2004","article-title":"IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1","volume":"287","author":"Sacheck","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819300118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819300118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:05:02Z","timestamp":1760911502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819300118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":139,"alternative-id":["S1043661819300118"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.010","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of statin-associated skeletal muscle-associated symptoms","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104201"}}